Abstract Details
Ralf Reilmann, MD, FAAN
(George-Huntington-Institute)
PRESENTER |
The institution of Dr. Reilmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. The institution of Dr. Reilmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for uniQure. The institution of Dr. Reilmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for WAVE. Dr. Reilmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WAVE. The institution of Dr. Reilmann has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for IOS-Press. The institution of Dr. Reilmann has received research support from European Union. Dr. Reilmann has a non-compensated relationship as a Executive Committee Member with Huntington Study Group that is relevant to AAN interests or activities. Dr. Reilmann has a non-compensated relationship as a Member of Executive Committee with European Huntington Disease Network that is relevant to AAN interests or activities. Dr. Reilmann has a non-compensated relationship as a Co-Chair Task Force on Huntington Disease with Movement Disorders Socitey that is relevant to AAN interests or activities. |
Mark F. Gordon, MD, FAAN (Teva Pharmaceuticals) | Dr. Gordon has received personal compensation for serving as an employee of Teva. Dr. Gordon has stock in Teva. |
Karen E. Anderson | Ms. Anderson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for teva. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AskBio. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Biogen. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Ms. Anderson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for neurocrine. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medscape. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for atheneum. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GLG. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a scientific advisor with CHDI. |
Andrew S. Feigin, MD (NYU Langone Health) | Dr. Feigin has received personal compensation for serving as an employee of Rho, Inc.. Dr. Feigin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kenai. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ADCS/ATRI. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Feigin has received research support from Huntngton Study Group. The institution of Dr. Feigin has received research support from Prilenia. |
Sarah J. Tabrizi, MD, PhD | Sarah J. Tabrizi, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for F. Hoffmann-La Roche Ltd. Sarah J. Tabrizi, MD, PhD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. |
Blair Leavitt, MD (University of British Columbia) | Dr. Leavitt has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Incisive Genetics. Dr. Leavitt has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Leavitt has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design TX. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReMix Tx. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Tx. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Leavitt has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Incisive Genetics. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Huntington's Disease. Dr. Leavitt has stock in Incisive Genetics. Dr. Leavitt has stock in SRNAlytics. The institution of Dr. Leavitt has received research support from CIHR. The institution of Dr. Leavitt has received research support from HSC. The institution of Dr. Leavitt has received research support from Brain Canada. The institution of Dr. Leavitt has received research support from NMIN. Dr. Leavitt has received intellectual property interests from a discovery or technology relating to health care. |
No disclosure on file | |
Paola Piccini, MD (Hammersmith Hospital) | No disclosure on file |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
Juha M. Savola, MD, PhD (Spark Therapeutics, Inc) | Dr. Savola has received personal compensation for serving as an employee of Teva Pharmaceuticals. Dr. Savola has received intellectual property interests from a discovery or technology relating to health care. |
No disclosure on file |